The State of Women's Health in 2026: Data Report
The State of Women's Health in 2026
A data-driven analysis of the treatment gaps affecting millions of American women
Published by Amie | March 2026 | Data from CDC, KFF, McKinsey, NIH, and peer-reviewed studies
Women in the United States face a paradox: they use healthcare more than men, yet receive worse outcomes for many conditions. From menopause to sexual health to weight management, the data reveals a consistent pattern: conditions that disproportionately affect women are under-researched, under-diagnosed, and under-treated.
This report synthesizes the latest published data across five critical areas of women's health, revealing the scope of the treatment gap and the emerging solutions closing it.
1. The Menopause Crisis: 80% Symptomatic, Most Untreated
Approximately 6,000 women reach menopause every day in the United States, totaling 1.3 million annually. Despite its universality, menopause remains one of the most poorly addressed health transitions in modern medicine.
Only 49% of women in perimenopause and 58% in postmenopause discuss symptoms with their doctor. Among those who do, many report being dismissed or offered only antidepressants rather than targeted hormone therapy. In the UK, where tracking is more robust, only 14% of menopausal women use HRT despite its established efficacy.
2. Female Sexual Health: The Most Under-Treated Condition in Medicine
Female sexual dysfunction (FSD) affects nearly half of all women, yet receives a fraction of the research funding and clinical attention devoted to male sexual health conditions.
| FSD Domain | Pooled Prevalence |
|---|---|
| Low Sexual Desire | 50.7% |
| Arousal Disorder | 48.2% |
| Orgasm Disorder | 40.2% |
| Pain Disorder | 39.1% |
| Lubrication Problems | 37.6% |
More women experience sexual dysfunction than men, yet these conditions receive significantly less clinical attention, research funding, and pharmaceutical development. Most medical schools have only recently begun incorporating female sexual dysfunction into their curricula. The result: millions of women suffering in silence from treatable conditions.
3. GLP-1 Medications: Women Leading Adoption
Women are driving the GLP-1 revolution, using weight loss medications like semaglutide and tirzepatide at nearly double the rate of men, particularly during the metabolically vulnerable years around menopause.
| Metric | Women | Men |
|---|---|---|
| Ever used GLP-1 | 22% | 14% |
| Currently using GLP-1 | 15% | 9% |
| Average weight loss | 10.9% | 6.8% |
| Planning to use in 2025 | 30% | 20% |
4. Hair Loss in Women: The Hidden Epidemic
While 40% of women show signs of hair loss by age 50, hair loss remains culturally associated with men. Women report feeling isolated and ashamed, with 85% experiencing reduced self-esteem. Causes cited include stress/anxiety (50%), postpartum changes (24%), aging (20%), and menopause (16%). Treatment-seeking is rising, with female hair restoration patients up 16.5% since 2021.
5. The Healthcare Dismissal Gap
Across all health conditions, women face a systemic pattern of dismissal, delayed diagnosis, and under-treatment that compounds every issue above.
6. Telehealth: Closing the Gap
Women are increasingly turning to telehealth to bypass the barriers of traditional healthcare, with virtual care visits for women's health surging dramatically.
Every woman deserves personalized, evidence-based care.
Amie connects women with board-certified physicians for personalized treatment plans, from menopause management and sexual wellness to medical weight loss and longevity, all from the privacy of home.
Explore Amie's TreatmentsMethodology
This report aggregates data from peer-reviewed studies published in PubMed/PMC, government datasets (CDC, NIH), industry reports (McKinsey, Deloitte, KFF), and validated surveys (RAND, Midi Health, Bonafide State of Menopause). All statistics are sourced from publications dated 2022-2026. Where ranges exist, we report pooled estimates from meta-analyses. This report presents secondary analysis of published data and does not include original survey research.
References
- Midi Health. "Menopause Statistics." 2024. joinmidi.com
- Pharmavite. "5th Annual State of Menopause Study." 2025.
- Bonafide. "State of Menopause 2025." hellobonafide.com
- Impacts of Menopause. Economic impact analysis. 2024.
- PMC. "Female Sexual Dysfunction Prevalence: Systematic Review and Meta-Analysis." PMC12481727, 2025.
- Medical Xpress. "Sexual dysfunction in women at midlife explored." Nov 2025.
- KFF. "1 in 8 Adults Say They Are Currently Taking a GLP-1 Drug." 2025.
- RAND Corporation. GLP-1 usage survey. PMC12711338, 2025.
- HealthVerity. "GLP-1 Trends 2025: Real-World Data." 2025.
- Axios. "Ozempic, weight loss, and women: The menopause connection." June 2025.
- ISHRS. "2025 Practice Census Results." ishrs.org, 2025.
- Hers/ForHers. "Women and Hair Thinning." forhers.com, 2025.
- KFF. "Negative Interactions Experienced by Women in Health Settings." 2024.
- Deloitte. "Why Women Skip or Delay Health Care." 2024.
- McKinsey Health Institute. "Closing the Women's Health Gap: A $1 Trillion Opportunity." 2024.
- Wheel. "Virtual Care Horizons: Women's Health Telehealth Trends." 2025.
- CDC/NCHS. "Telemedicine Use Among Adults: United States, 2021-2022." 2024.
- Johns Hopkins. "GLP-1 Weight Loss Drugs Comparably Effective Across Demographics." 2026.